A Phytoestrogen Diarylheptanoid Mediates Estrogen Receptor/Akt/Glycogen Synthase Kinase 3β Protein-dependent Activation of the Wnt/β-Catenin Signaling Pathway

Background: Diarylheptanoid (ASPP 049) isolated from C. comosa exhibits high estrogenic activity. Results: ASPP 049 rapidly induced β-catenin accumulation in the nucleus and activated TCF/LEF-mediated activation of Wnt/β-catenin signaling. Conclusion: ASPP 049 from C. comosa induces preosteoblastic cell proliferation and differentiation through activation of Wnt/β-catenin signaling. Significance: Providing a scientific rationale for using C. comosa as a dietary supplement to prevent bone loss in postmenopausal women.

Estrogen promotes growth in many tissues by activating Wnt/β-catenin signaling. Recently, ASPP 049, a diarylheptanoid isolated from Curcuma comosa Roxb., has been identified as a phytoestrogen. This investigation determined the involvement of Wnt/β-catenin signaling in the estrogenic activity of this diarylheptanoid in transfected HEK 293T and in mouse preosteoblastic (MC3T3-E1) cells using a TOPflash luciferase assay and immunofluorescence. ASPP 049 rapidly activated T-cell-specific transcription factor/lymphoid enhancer binding factor-mediated transcription activity and induced β-catenin accumulation in the nucleus. Interestingly, the effects of ASPP 049 on the transcriptional activity and induction and accumulation of β-catenin protein in the nucleus of MC3T3-E1 cells were greater compared with estradiol. Activation of β-catenin in MC3T3-E1 cells was inhibited by ICI 182,780, suggesting that an estrogen receptor is required. In addition, ASPP 049 induced phosphorylations at serine 473 of Akt and serine 9 of GSK-3β. Moreover, ASPP 049 also induced proliferation and expressions of Wnt target genes Axin2 and Runtx2 in MC3T3-E1 cells. In addition, ASPP 049 increased alkaline phosphatase expression, and activity that was abolished by DKK-1, a blocker of the Wnt/β-catenin receptor. Taken together, these results suggest that ASPP 049 from C. comosa induced osteoblastic cell proliferation and differentiation through ERα-, Akt-, and GSK-3β-dependent activation of β-catenin signaling. Our findings provide a scientific rationale for using C. comosa as a dietary supplement to prevent bone loss in postmenopausal women.

The Wnt/β-catenin signaling pathway has been demonstrated to be responsible for a variety of biological processes, including tissue homeostasis and cancer. Cytosolic β-catenin protein is the principal mediator of Wnt signaling (1). In the absence of extracellular Wnt ligands, β-catenin is recruited into a destruction complex comprising Axin, adenomatous polyposis coli (APC), and glycogen synthase kinase 3β (GSK-3β) (2). Axin and APC act as the scaffolding proteins that facilitate GSK-3β to phosphorylate β-catenin at amino acid residues 33, 37, and 41 and target it for ubiquitination by β-transducin repeat-containing homologue protein (β-TrCP) in proteasome. Thus, the cytosolic β-catenin level is kept low. In the presence of Wnt ligands, on the other hand, Wnt protein binds to its coreceptors Frizzled (Fz) receptor, a seven-transmembrane protein, and a low-density lipoprotein receptor-related protein (LRP). This binding activates Dishevelled (Dvl) protein, which then inhibits the formation of Axin-APC-GSK-3β destruction complex. Therefore, GSK-3β-mediated phosphorylation of β-catenin is inhibited. Non-phosphorylated β-catenin is not targeted for degradation and is accumulated in the cytoplasm. It translocates into the nucleus, binds with T-cell-specific transcription factor/lymphoid enhancer binding factor (TCF/LEF), and activates target gene expression. Many of the Wnt target genes are responsible for several cellular processes such as cell proliferation, differentiation, transformation, migration, and adhesion (3).

Wnt and estrogen signaling play critical roles both in normal development and diseases. The interactions between these two signaling pathways have been reported in many tissues. Several
Diarylheptanoid Activates Wnt/β-Catenin Signaling Pathway

physiological consequences associated with estrogen signaling, such as neuronal development (4) and bone formation (5), are mediated through the activation of the Wnt/β-catenin signaling pathway. Thus, in neuroblastoma cells and primary cortical neurons, estradiol increased cytosolic β-catenin protein levels and activated the transcriptional activity of Wnt/β-catenin signaling by an inhibition of GSK-3β functions (4). Also, in bone cells, the transcriptional activity of Wnt/β-catenin signaling was activated by binding between the TCF and estrogen receptor (6). Mutation in low-density lipoprotein receptor-related protein 5 (LRP5) was shown to cause osteoporosis pseudo-osteo-hippocampal syndrome (7), which is characterized by low bone mass. In contrast, mutant mice that overexpressed the constitutive active LRP5 (G171V) in osteoblasts exhibited an enhanced osteoblastic activity, a reduction in osteoblast apoptosis, and high bone mass phenotype (8). It is well established that estrogen deficiency is associated with bone loss (9), whereas administration of estrogen inhibits bone resorption by reducing osteoclasts number and is mediated via the estrogen receptor (10). Thus, both estrogen and Wnt/β-catenin signaling pathways play an important role in bone remodeling. Therefore, the regulation of the Wnt/β-catenin signaling pathway and estrogen replacement therapy are considered as the effective treatments for bone loss. However, long-term supplementation with estrogen increased the risk of breast cancer (11) and endometrial cancer (12). In view of these undesirable effects, the development of drugs with a lower risk of cancer is needed.

Phytoestrogens are a diverse group of naturally occurring non-steroidal plant compounds that exert estrogenic-like activity and become one of the alternative interventions for treatment of menopausal symptoms. Curcuma comosa Roxb. (C. comosa) has long been used in Thai traditional medicine for treatments of illness in the uterus and ovarian hormone deficiency (13). C. comosa exhibits an estrogen-like activity and induces cornification of the vaginal epithelium in the smear and keratinization of the mucosal surface of the vagina (13). Recently, a study reported that the hexane extract of this plant prevented bone loss induced by estrogen deficiency (14). However, the molecular mechanism underlying the effect of C. comosa in protecting bone loss is still unknown. A number of diarylheptanoids have been isolated from C. comosa. Of these, ASPP 049 ((3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol) is the major component (15), which exhibits high estrogenic activity (16). ASPP 049 mediated transcriptional activation through a ligand-dependent ERα-estrogen-responsive element-driven pathway (17) and a non-genomic action on vascular relaxation through the ER-Akt-endothelin nitric oxide synthase pathway (18). However, the estrogenic activity of this compound in relation with Wnt/β-catenin signaling, which is associated with bone cell proliferation and differentiation, has not yet been investigated.

In this study, we reported for the first time the non-genomic action of a novel phytoestrogen, ASPP 049, from C. comosa on Wnt/β-catenin signaling and osteogenesis. ASPP 049 mediates the ER/Akt/GSK-3β-dependent activation of the Wnt/β-catenin signaling pathway and induces preosteoblastic cell proliferation and differentiation. Therefore, this compound may have a potential use as an osteogenic agent to protect osteoporosis in postmenopausal women.

MATERIALS AND METHODS

Cell Culture and Transfection—HEK 293T cells and mouse preosteoblastic (MC3T3-E1) cells were obtained from the ATCC and cultured in minimal essential medium and minimal essential medium α modification supplemented with 10% fetal bovine serum (Invitrogen), respectively. Cells were incubated at 37 °C under a 5% CO2 incubator. HEK 293T and MC3T3-E1 cells were transfected using Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer. For the differentiation assay, cells were cultured in differentiation medium, which was growth medium containing β-glycerophosphate (10 mm), ascorbic acid (50 μg/ml), and CaCl2 (2 mm), for 5 days prior to treatments with test compounds.

Plasmids, Antibodies, Reagents, and ASPP 049 from C. comosa—β-catenin-FLAG was generated as described previously (19). The following reagents were used: 17β-estradiol (E2) from Sigma-Aldrich; ICI 182,780 from Tocris Cookson, Inc; charcoal-stripped fetal bovine serum, TRIZol reagent from Invitrogen; BCA from Pierce; complete Mini EDTA-free from Roche; dual luciferase reporter assay from Promega; cDNA kit from Bio-Rad; SYBR kit from Biosystem, SuperSignal West Pico chemiluminescent from ThermoScientific; and recombinant human Dickkopf-related protein 1 (DKK-1) from R&D Systems. The following antibodies were used: anti-β-catenin (H-102) from Santa Cruz Biotechnology, Inc.; anti-diphosphorylated β-catenin (anti-ABC) clone 8E7 monoclonal antibody from Millipore; anti-β-actin from Sigma-Aldrich; anti-phospho-GSK-3β (Ser-9), anti-GSK-3β, anti-phospho-Akt (Ser-473), and anti-Akt from Cell Signaling Technology; HRG goat anti-mouse IgG (H+L), and HRG goat anti-rabbit IgG (H+L) antibodies from Jackson Immuno Research Laboratories, Inc; and goat anti-mouse IgG (H+L) Alexa Fluor 568, goat anti-rabbit IgG (H+L) Alexa Fluor 488, and TO-PRO3 from Invitrogen. ASPP 049 was isolated and purified as described previously (15).

Luciferase Reporter Assay—HEK 293T cells were maintained in phenol red-free minimal essential medium containing 10% dextan-coated charcoal FBS (stripped FBS, SFBS) for 48 h prior to use in the experiments. At 60–70% confluence, HEK 293T cells grown in 96-well culture plates were transiently transfected with 0.2 μg of mERα plasmid. After 24 h, the transfected cells were then transiently transfected with 0.1 μg of TOPflash TCF reporter plasmid, 0.01 μg of Renilla luciferase reporter plasmid, which was used to evaluate the efficiency of transfection, and 0.1 μg of β-catenin-FLAG plasmid using Lipofectamine 2000 according to the instructions of the manufacturer. 48 h after the first transfection, cells were treated with different concentrations of E2 and ASPP 049 and incubated for various times, as indicated in the individual experiments. Luciferase activities were measured using the dual-luciferase reporter assay system (Promega) according to the recommendations of the manufacturer. The firefly luciferase activity was normalized to Renilla luciferase activity and expressed as the fold change compared with the cells transfected with the pcDNA3.1 empty vector alone.
Diarylheptanoid Activates Wnt/β-Catenin Signaling Pathway

Western Blot Analysis—Cells were lysed with modified radioimmunoprecipitation assay lysis buffer (50 mM Tris-HCl (pH7.4), 150 mM NaCl, 1 mM EDTA, 1% TritonX-100, 1 mM NaF, 1 mM NaVO₃, 1 mM PMSF, and protease inhibitor mixture (Roche)). After 20-min incubation on ice, cells were subjected to brief sonication and centrifugation at 14,000 × g for 20 min. The supernatants were collected, and the protein concentration was measured. An equal amount of protein was used for Western blot analysis. Protein was resolved by SDS-PAGE; subsequently transferred to a nitrocellulose membrane by electroblotting; and probed with indicated antibodies, anti-β-catenin, anti-phospho-GSK3 (Ser-9), anti-GSK-3β, anti-phospho-Akt (Ser-473), anti-Akt, and anti-β-actin antibodies. The signal was detected using the enhanced SuperSignal West Pico chemiluminescent.

Immunofluorescence Microscopy—MC3T3-E1 cells were grown on glass coverslips in 24-well culture plates. At 60–70% confluence, cells were treated with 0.1 μM ASPP 049 or E2 for 60 min. Cells were washed with cold PBS containing Ca²⁺/Mg²⁺ (PBS⁺), fixed with cold methanol for 10 min, and permeabilized with permeabilizing buffers (0.3% Triton X-100 and 0.3% BSA) for 30 min. The samples were then incubated with mouse anti-dephosphorylated β-catenin and rabbit anti-β-catenin diluted in 5% normal goat serum and left overnight at 4°C. Cells were washed with 0.3% Triton X-100 in PBS² for 5 times and then incubated with Alexa Fluor 488 goat anti-rabbit IgG (H+L) and Alexa Fluor 568 goat anti-mouse IgG (H+L) diluted in 5% normal goat serum for 1 h. Cells were washed with 0.3% Triton X-100 in PBS² five times, stained with TO-PRO3 (Molecular probes) for 15 min. The stained coverslips were mounted and visualized at room temperature with a confocal laser microscope (FV10i/w, Olympus).

Total RNA Isolation and RT-PCR Quantification—MC3T3-E1 cells were treated with 0.1 μM E2 or ASPP 049 at various time points. Total RNAs were extracted from treated MC3T3-E1 cells using TRIzol reagent according to the recommendations of the manufacturer with a slight modification. Briefly, cells using TRIzol reagent according to the recommendation of the manufacturer (Bio-Rad). Quantitative real-time PCRs of Axin2, RUNX2, ALP, and COL1A1 were performed on an equal amount of cDNA using KAPA SYBR® FAST quantitative PCR kit according to the instructions of the manufacturer (Kapa Biosystems) with the ABI PRISM 7500 sequence detection system and analysis software (Applied Biosystems). The primers used were as follows: Axin2, 5′-TGACTCTCTCTCTCCAGATCCCA-3′ and 5′-TGCCACACTAGTGTCGACA-3′, NM_015732; Runx2, 5′-CTGACGTGCCAGGCCTATT-3′ and 5′-GCACTTCGTGGTCTCTTCTT-3′, NM_001145920; ALP, 5′-AGAGCCGACCCGATGCAACA-3′ and 5′-AATGCCACGGGACCTCCAGC-3′, NM_007431; COL1A1, 5′-TCGAGCTCAGGGCAGGGCAGG-3′ and 5′-CGTGTGACTCTGTGACGCGT-3′, NM_007742; and GAPDH, 5′-CGAGACCCTACTAACATC AAA-3′ and 5′-TTTGGCTCCACCCTTCAAG-3′, NM_008084.

Alkaline Phosphatase Assay—For the ALP staining assay, MC3T3-E1 cells were cultured in differentiation medium and treated with 0.1 μM E2 or various concentrations of ASPP 049 for 21 days. After treatments, cells were washed with PBS containing Ca²⁺/Mg²⁺ (PBS⁺), fixed with a fixative solution for 1 min, and washed three times with deionized water. Cells were incubated in buffer containing 0.4 mg/ml Naphthol AS-MX phosphate disodium salt (Sigma) and 1 mg/ml Fast Blue RR salt (Sigma) for 15 min, washed with deionized water, and observed under a light microscope. For the ALP activity assay, MC3T3-E1 cells were cultured in differentiation medium for 5 days and then treated with 0.1 μM E2 or various concentrations of ASPP 049 in differentiation medium for 7 days. Cells were harvested with lysis buffer containing 0.2% Triton X-100, 1 mM DTT, and 100 mM potassium phosphate buffer (pH 7.8). ALP activity was determined by mixing the cell extract with 5 mM freshly prepared p-nitrophenyl phosphate (Sigma) substrate in 0.1 mM glycine (pH 10.4), 2 mM MgCl₂, and 1 mM ZnCl₂ at room temperature for 60 min, the enzymatic reaction was stopped by adding 3 mM NaOH solution, and absorbance was measured at 405 nm. ALP activity was normalized to total protein concentration by using the BCA method. For the DKK-1 inhibition study, cells were pretreated with 0.2 μg/ml of DKK-1 for 3 h before the application of ASPP 049 or E2.

Statistical Analysis—Statistical significance was determined by a two-tailed unpaired Student’s t test or one-way ANOVA followed by post hoc (Bonferroni) multiple comparisons between treatment groups using GraphPad Prism version 4.0 for Windows (GraphPad Software, San Diego, CA). p < 0.05 was considered statistically significant.

RESULTS

ASPP 049 Activates the Canonical Wnt/β-Catenin Signaling Pathway—Estradiol (E2) has been reported to activate TCF/LEF-mediated transcription activity in neuronal cells (20) and bone cells (8). To evaluate whether ASPP 049, which exhibits an estrogenic-like activity (17), activates the Wnt/β-catenin signaling pathway, a TOPflash reporter assay in HEK 293T cells was employed by transient transfection with TOPflash, mERo, β-catenin-FLAG, and Renilla plasmids. As shown in Fig. 1A, expression of β-catenin induced an up-regulation of the canonical Wnt/β-catenin activity as indicated by enhanced luciferase activity. ASPP 049 exhibited both time- and concentration-dependent activations of Wnt/β-catenin signaling. At a concentration of 50 μM, the increase in TOPflash luciferase activity peaked at 60 min after treatment (Fig. 1A), whereas maximum activation occurred in the presence of ASPP 049 at 0.1 μM (B). The molecular mechanisms by which this diarylheptanoid and
ASPP 049 Induces TCF/LEF-dependent Activation of Wnt/β-Catenin Signaling through Up-regulation of the β-Catenin Protein in Preosteoblastic Cells—The Wnt/β-catenin signaling pathway plays an important role in bone mass homeostasis. Recently, we have demonstrated that the hexane extract of C. comosa mediates TCF/LEF-dependent activation of the canonical Wnt/β-catenin signaling, similar to that of E2. Interestingly, ASPP 049 had a greater (p < 0.001) effect than E2 at the same concentration.

E2 regulate TCF/LEF-dependent activation of Wnt/β-catenin activity were evaluated in HEK 293T cells transfected with TOPflash and FOPflash, the LEF mutant reporter plasmid, after treatment with 0.1 μM ASPP 049 or 0.1 μM E2 for 60 min. In the TOPflash-transfected cells, β-catenin expression led to an up-regulation of the Wnt/β-catenin activity. Treatment with ASPP 049 or E2 further enhanced the increase in luciferase activity induced by β-catenin expression. In contrast, the activation of Wnt/β-catenin activity was not observed in FOPflash-transfected HEK 293T cells (Fig. 1C). These data suggest that ASPP 049 from C. comosa mediates TCF/LEF-dependent activation of the canonical Wnt/β-catenin signaling, similar to that of E2.}

**ASPP 049 induces TCF/LEF-dependent activation of Wnt/β-catenin signaling through up-regulation of the β-catenin protein in preosteoblastic cells**

**Catenin Signaling Pathway**

**Diarylheptanoid Activates Wnt/β-Catenin Signaling**

**A**. time-dependent activation of TCF/LEF reporter activity by ASPP 049. HEK 293T cells were transiently cotransfected with TOPflash, β-catenin-FLAG, ERα, and Renilla luciferase vectors. After 48 h, cells were treated with ASPP 049 for the indicated time. Activity of the β-catenin signaling was quantified by measuring the relative firefly luciferase activity units normalized to Renilla luciferase activity. Data are expressed as the fold change compared with the cells transfected with pcDNA3.1 empty vector. 

**B**. concentration-dependent activation of TCF/LEF reporter activity by ASPP 049. HEK 293T cells were transiently cotransfected with TOPflash, β-catenin-FLAG, ERα, and Renilla luciferase vectors. After 48 h, cells were treated with the indicated concentration of ASPP 049 for 60 min and harvested for luciferase-based TOPflash assay for Wnt signaling. 

**C**. ASPP 049 and E2 activate TCF/LEF-driven luciferase activity. HEK 293T cells were transfected with the indicated plasmids. Treatment with ASPP 049 or E2 (60 min, 0.1 μM) selectively increased transcription from the TOPflash reporter plasmid compared with FOPflash. Data are represented as corrected luciferase: means ± S.E. (n = 4). *p < 0.05; **p < 0.01; ***p < 0.001 compared with β-catenin-FLAG-transfected cells and treatment with vehicle (ANOVA). ###, p < 0.001 compared with β-catenin-FLAG-transfected cells and treatment with E2 (Student’s t test).
lated β-catenin. As illustrated in Fig. 3B, MC3T3-E1 cells treated with ASPP 049 and E2 showed nuclear accumulation of the activated β-catenin. Again, ASPP 049 exhibited a greater effect than that of E2. These data demonstrate that both compounds activate Wnt/β-catenin signaling by promoting nuclear localization of β-catenin protein.

GSK-3β-, Akt- and ER-dependent Activation of Canonical Wnt Signaling by ASPP 049 and E2 in Preosteoblastic Cells—Because GSK-3β phosphorylates β-catenin and prevents TCF-activated transcription activity, we next determined whether the activation of Wnt/β-catenin signaling mediated by ASPP
Diarylheptanoid Activates Wnt/β-Catenin Signaling Pathway

OCTOBER 19, 2012• VOLUME 287 • NUMBER 43 • JOURNAL OF BIOLOGICAL CHEMISTRY 36173

049 involves GSK-3β. To address this question, we used the constitutively active β-catenin mutant S33Y, which is insensitive to GSK-3β-mediated phosphorylation. HEK 293T cells were transiently cotransfected with TOPflash, Renilla luciferase vector, and the indicated plasmids. After 24 h, cells were incubated with 0.1 μM ASPP 049 or 0.1 μM E2 for 60 min. Activity of the β-catenin signaling pathway was quantified by measuring the relative firefly luciferase activity units normalized to Renilla luciferase activity. Data is expressed as fold change compared with pcDNA3.1-transfected cells and represented as mean ± S.E. (n = 4). **, p < 0.01; *** p < 0.001 compared with β-catenin-FLAG-transfected cells treated with vehicle (ANOVA); #, p < 0.05 compared with β-catenin-FLAG-transfected cells and treatment with E2 (Student’s t test).

FIGURE 4. Activation of Wnt/β-catenin signaling by ASPP 049 and E2 is GSK-3β- and Akt-dependent. A, GSK-3β-dependent activation of Wnt/β-catenin signaling. The activation of Wnt/β-catenin signaling by ASPP 049 or E2 was measured in the presence of constitutively active β-catenin mutant S33Y, which is insensitive to GSK-3β-mediated phosphorylation. HEK 293T cells were transiently cotransfected with TOPflash, Renilla luciferase vector, and the indicated plasmids. After 24 h, cells were incubated with 0.1 μM ASPP 049 or 0.1 μM E2 for 60 min. Activity of the β-catenin signaling pathway was quantified by measuring the relative firefly luciferase activity units normalized to Renilla luciferase activity. Data is expressed as fold change compared with pcDNA3.1-transfected cells and represented as mean ± S.E. (n = 4). **, p < 0.01; *** p < 0.001 compared with β-catenin-FLAG-transfected cells treated with vehicle (ANOVA); #, p < 0.05 compared with β-catenin-FLAG-transfected cells and treatment with E2 (Student’s t test). B, ASPP 049 and E2 induce GSK-3β-dependent β-catenin expression. MC3T3-E1 cells were pretreated with 40 mM LiCl or 40 mM NaCl for 16 h and then incubated in medium containing 0.1 μM ASPP 049 or 0.1 μM E2 for 60 min. Cells were harvested and analyzed by Western blotting using anti-β-catenin and anti-β-actin antibodies. ASPP 049 and E2 failed to increase β-catenin expression after LiCl pretreatment.

C, ASPP 049 and E2 increase GSK-3β and Akt phosphorylation in MC3T3-E1 cells. MC3T3-E1 cells were treated with 0.1 μM ASPP 049 or 0.1 μM E2 for different times (30–120 min) and then harvested for Western blotting using anti-phospho-GSK-3β (Ser-9), anti-GSK-3β, anti-phospho-Akt (Ser-473), and anti-Akt antibodies. DMSO, dimethyl sulfoxide. D, LY 294002 blocks ASPP 049- and E2-induced GSK-3β and Akt phosphorylation. MC3T3-E1 cells were treated with 0.1 μM ASPP 049 or 0.1 μM E2 for 60 min with or without pretreatment with LY 294002, a specific PI3 Kinase inhibitor (10 μM for 3 h), and then harvested for Western blotting using the indicated antibodies.

The phosphorylation of Akt at serine 473 residues resulted in its activation and, therefore, promoted GSK-3β phosphorylation at serine 9 (21). Moreover, it has recently been shown that E2 inhibited GSK-3β activity via the PI3K/Akt signaling pathway in neurons (22). To test whether ASPP 049-mediated GSK-3β-dependent activation of Wnt/β-catenin signaling proceeds through the activation of the PI3K/Akt pathway, MC3T3-E1 cells were pretreated with 40 mM LiCl or 40 mM NaCl for 16 h and then incubated in medium containing 0.1 μM ASPP 049 or 0.1 μM E2 for 60 min. Cells were harvested and analyzed by Western blotting using anti-β-catenin and anti-β-actin antibodies. ASPP 049 and E2 failed to increase β-catenin expression after LiCl pretreatment.
cells were treated with 0.1 μM ASPP 049 or 0.1 μM E2 for 30–120 min, lysed for immunoblotting using anti-phospho-GSK-3β (Ser-9) and anti-phospho-Akt (Ser-473) antibodies. As shown in Fig. 4C and supplemental Fig. S1, E2 and ASPP 049 induced phosphorylations of GSK-3β and Akt in a time-dependent manner. In addition, E2 and ASPP 049 failed to induce phosphorylations of GSK-3β (Ser-9) and Akt (Ser-473) in the cells preincubated with LY 294002, a PI3K inhibitor (Fig. 4D).

These observations indicate that ASPP 049 and E2 induced the phosphorylation of Akt at serine 473 and subsequently activated the phosphorylation of GSK-3β at serine 9, leading to inhibition of GSK-3β activity and, hence, activation of Wnt/β-catenin signaling.

A previous study showed the involvement of ERα in Wnt/β-catenin signaling in osteoblastic cells (5). To determine whether ERα plays a role in the regulation of β-catenin in preosteoblastic cells, we treated MC3T3-E1 cells with ICI 182,780 (an ER blocker) for 2 h prior to treatment with ASPP 049 or E2. As shown in Fig. 5, both compounds significantly increased the level of β-catenin protein, but the expression was decreased by pretreatment with ICI 182,780. Moreover, the induction of Akt and GSK-3β phosphorylations mediated by ASPP 049 and E2 was abolished in the presence of ICI 182,780 (supplemental Fig. S2). These data strongly suggest that ERα is required for the activation of Wnt signaling by ASPP 049 and E2 in MC3T3-E1 cells.

ASPP 049 and E2 Induce Preosteoblastic Cell Proliferation and the Expression of Wnt Target Genes—Because Wnt/β-catenin signaling regulates cell proliferation and differentiation of multiple tissues, including bone cells, we then assessed the proliferative effects of ASPP 049 and E2 on preosteoblastic cells using an MTT assay. Only a slight increase in cell proliferation occurred after treatment with E2 for 24 h, whereas a marked enhancement was observed after ASPP 049 treatment. In addition, activation of Wnt/β-catenin signaling by specific inhibition of GSK-3β activity using LiCl produced a profound and sustained increase in preosteoblastic cell proliferation from 24 to 120 h (Fig. 6A). The results suggest that ASPP 049-mediated Wnt/β-catenin activation induces bone cell proliferation. This effect was further confirmed by the expression of Wnt target genes. MC3T3-E1 cells were treated with 0.1 μM ASPP 049 or 0.1 μM E2 at various time points (1–48 h), and quantitative real
**Diarylheptanoid Activates Wnt/β-Catenin Signaling Pathway**

**FIGURE 6. ASPP 049 and E2 enhance cell proliferation and Wnt target gene expression.** A, ASPP 049 increases MC3T3-E1 cell proliferation. MC3T3-E1 cells were treated with 0.1 μM ASPP 049, 0.1 μM E2 or 10 mM LiCl for the indicated times. The proliferation of MC3T3-E1 cells was observed by MTT assay. Cell proliferation is expressed as % of control group (dimethyl sulfoxide, DMSO). B and C, ASPP 049 and E2 increase Wnt target gene expression. MC3T3-E1 cells were treated with 0.1 μM ASPP 049 or 0.1 μM E2 for the indicated times (1, 6, 24, and 48 h). Total RNAs were extracted for quantitative PCR of the Wnt target genes: Axin2 (B) and RUNX2 (C). Data are represented as mean ± S.E. (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared with vehicle control treatments (ANOVA).

ASPP 049 induced a transient elevation of Axin2 mRNA at 1 h, followed by a reduction during 6–24 h and then a marked increase at 48 h. Interestingly, the effect of ASPP 049 at 1 h was significantly greater, but at 48 h it was not different from that of E2. The expression profiles of RUNX2 mRNA following treatment with these two estrogenic compounds were similar to those of Axin2. Thus, transient increases in 1 h followed by decreases at 6 h were also observed (Fig. 6C). Nonetheless, the level of expression returned to control (after E2) or was higher than control (after ASPP 049) at 24 h. Because RUNX2 plays a role as an early transcription factor essential for osteoblast differentiation, our data suggest that ASPP 049-activated Wnt/β-catenin signaling may enhance differentiation of preosteoblast cells. Collectively, our results indicate that ASPP 049 and E2 increase preosteoblastic cell proliferation and may enhance differentiation through the mechanisms related to activation of Wnt target gene expression, including Axin2 and Runx2.

ASPP 049 and E2 Induce Preosteoblastic Cell Differentiation via Wnt/β-Catenin Signaling—To determine the effect of ASPP 049 in promoting preosteoblastic cell differentiation, MC3T3-E1 cells were cultured in differentiation medium with ASPP 049 (0.1–10 μM) for 21 days. As shown in Fig. 7A, ASPP 049 induced the expression of ALP, a bone differentiation marker, in a dose-dependent manner. To confirm the induction of ALP expression, ALP activity was assayed in MC3T3-E1 cells after treatment with ASPP 049 at various concentrations (0.01–10 μM) or E2 (0.1 μM) for 7 days. Consistent with ALP staining, ASPP 049 induced a dose-dependent increase in ALP activity (Fig. 7B). In addition, the expression of ALP and its activity were increased significantly after treatment with E2. This effect was further confirmed by the up-regulation of bone differentiation marker genes, including ALP and COL1A1. MC3T3-E1 cells were treated with various concentrations of ASPP 049 or 0.1 μM E2 for 14 days, and the quantitative real-time PCR was performed to determine the effect on ALP and COL1A1 mRNA expression. As shown in supplemental Fig. S3, A and B, both E2 and ASPP 049 induced significant increases in ALP and COL1A1 mRNA expression. To investigate whether the estrogenic compounds induced MC3T3-E1 cell differentiation through activation of the Wnt/β-catenin signaling pathway, MC3T3-E1 cells were pretreated with DKK-1, a blocker that prevents the binding of Wnt ligands to its receptors for signal induction, for 3 h before treatment with ASPP 049 or E2. Indeed, the ASPP 049- and E2-induced ALP activity was significantly inhibited by DKK-1 (Fig. 7C), indicating that ASPP 049 and E2 could act on the Wnt receptors. Collectively, our results strongly suggest that ASPP 049 and E2 increase preosteoblastic cell differentiation through the activation of the Wnt/β-catenin signaling pathway.

**DISCUSSION**

Wnt/β-catenin signaling has currently been recognized as an important regulator of bone mass and bone cell differentiation. It cross-talks with other signaling pathways, including estrogen receptor signaling (24). Both Wnt/β-catenin and estrogen receptor signaling pathways play an important role in bone remodeling, particularly in menopausal women (25). The main purpose of this study was to investigate the mechanisms by which a phytoestrogen isolated from *C. comosa*, ASPP 049, prevents bone loss in estrogen deficiency, with a specific emphasis on the activation of Wnt/β-catenin signaling. By using the ERα-Wnt/β-catenin expression system in HEK 293T cells and mouse preosteoblastic (MC3T3-E1) cells, we demonstrated that, indeed, this phytoestrogen activated the Wnt/β-catenin signaling pathway. The activation of Wnt/β-catenin signaling was ERα-/Akt-/GSK-3β-dependent. In addition, the compound increased the expressions of Wnt target genes (Axin2 and Runx2) and enhanced proliferation and differentiation of MC3T3-E1 cells. Taken together, our results strongly suggest that ASPP 049 promotes preosteoblastic cell proliferation and...
Diarylheptanoid Activates Wnt/β-Catenin Signaling Pathway

In preosteoblastic MC3T3-E1 cells, both E2 and ASPP 049 increased the expression of β-catenin protein, which was predominantly localized in the nucleus. It is known that in the absence of Wnt ligands, cytosolic β-catenin is kept low by GSK-3β-induced phosphorylation and subsequent degradation in the proteasome (2). Our finding that LiCl, which is a specific inhibitor of GSK-3β, and transfection with S33Y (a β-catenin mutant) in HEK 293T cells increased the expression of β-catenin protein and activity support the above notion. In addition, we also found that E2 and ASPP 049 induced phosphorylation of GSK-3β at the serine 9 residue. Furthermore, the activation of Wnt/β-catenin signaling by these estrogens was associated with phosphorylation of Akt at the serine 473 residue, suggesting that PI3K/Akt signaling is also involved, as in the neuroblastoma N2a-m cells (20). However, it is noteworthy that some differences exist between the effects of these two estrogens. Thus, ASPP 049 is more potent than E2 in activating cytosolic β-catenin expression, although it has weaker effects on Akt and GSK-3β phosphorylation. This is likely due to the fact that ASPP 049 has only a weak estrogenic activity compared with E2 (16). Another possible explanation for the different potency might be that the stabilization of β-catenin by ASPP 049 is mediated through additional signaling events that are independent of the canonical Wnt/β-catenin signaling. The canonical pathway is regulated by PI3K/Akt and involves the GSK-3β-induced phosphorylation of β-catenin and subsequent proteasome-mediated degradation. The alternative pathway for regulation of β-catenin levels is Akt/GSK-3β-independent. It is mediated by p53-induced expression of Siah-1 protein. Siah-1 interacts with Siah-interacting protein, Skp1, and Ebi. The latter protein binds and recruits β-catenin to the complex for proteasome-mediated degradation (26, 27). In addition, the cytosolic level of β-catenin is also regulated by the GSK-3β/Siah-independent pathway. Our previous study reported that tetraspanins reduced the cellular pool of β-catenin by enhancing the exosome-associated export of β-catenin from cells (28). Conversely, ASPP 049 might increase cytosolic β-catenin by reducing the exosomal transport from the cells. Alternatively, ASPP 049 is more efficient in translocating β-catenin into the nucleus. However, further experiments are required to completely understand the precise mechanisms through which activation of Wnt/β-catenin is mediated by ASPP 049.

FIGURE 7. ASPP 049-induced preosteoblastic cell differentiation is mediated by Wnt/β-catenin signaling. A, ASPP 049 induces ALP expression. MC3T3-E1 cells were cultured in differentiation medium and treated with various concentrations of ASPP 049 or E2 for 21 days. The ALP expression was stained with Naphthol AS-MX phosphate. DMSO, dimethyl sulfoxide. B, ASPP 049 induces ALP activity. MC3T3-E1 cells were cultured in differentiation medium and treated with 1 μM ASPP 049 or 0.1 μM E2 for 7 days with or without pretreatment with DKK-1 (0.2 μg/ml) for 3 h, as indicated. Cells were harvested, and ALP activity was measured at 405 nm and normalized with total protein. Data are expressed as fold change compared with the cells treated with vehicle control and are mean ± S.E. (n = 4). **, p < 0.01; ***, p < 0.001 compared with treatments (ANOVA). ##, p < 0.01; ###, p < 0.001 compared with the presence and absence of DKK-1 (Student's t test).
ASPP 049 slightly increased the phosphorylation levels of Akt on serine 473 as early as 30 min. However, marked stimulation of Akt phosphorylation was observed at 90 and 120 min (supplemental Fig. S1). The time course of Akt phosphorylation coincided with phosphorylation of GSK-3β (Fig. 4C). These effects of ASPP 049 resemble those of E2. Of interest, ASPP 049-induced phospho-Akt was less than that enhanced by E2, suggesting that additional mechanisms are involved in the effect of ASPP 049. Consistent with this notion, Akt-independent phosphorylation of GSK-3β has been reported. β-Br-cAMP and forskolin treatments resulted in the phosphorylation of GSK-3β at serine 9 residue in Rat1 and NIH3T3 cell lines, which were not altered by pretreatment with PI3K inhibitors, wortmannin, and LY294002 (29). A study in cerebellar granule neurons also showed that forskolin stimulated GSK-3β phosphorylation at serine 9 but not Akt phosphorylation at serine 473 (30). In addition, in human myoblasts, amino acids rapidly inactivated GSK-3β, demonstrated by increased serine 9 phosphorylation, whereas no significant change in protein kinase B/Akt activity was observed (31). Taken together, our results indicate that inactivation of GSK-3β induced by ASPP 049 occurred, at least in part, through the Akt-dependent mechanism.

Previously, our group has shown that ASPP 049 is the major phytoestrogen found in C. comosa and that the hexane extract of C. comosa protected bone loss in ovariectomized mice (14, 15). Our data, therefore, provide evidence suggesting that ASPP 049 may prevent bone loss by activating Wnt/β-catenin signaling as E2 does (5). However, a previous study reported that, in the absence of mechanical strain, E2 failed to induce β-catenin protein expression and transcription activity in ROS17/2.8 cells (5). This discrepancy could be due to the difference in the cell type used. It has recently been shown in preosteoblastic MC3T3-E1 cells that mechanically induced Cox-2 expression, which is involved in the synthesis of prostaglandins (a modulator of bone remodeling), is sensitized by E2 via ERα, whereas activation of Wnt signaling is diminished in the absence of mechanical stress (25). On the other hand, the synergy between activation of Wnt/β-catenin signaling by inhibition of GSK-3β and mechanical loading has been demonstrated in osteoblastic cells (5). Whether ASPP 049-induced activation of Wnt/β-catenin is modulated by mechanical force warrants further investigation. We have also shown in this study that activation of Wnt/β-catenin signaling by both E2 and ASPP 049 was diminished in the presence of a specific ER antagonist, ICI 182,780. The results corroborate well with the previous study showing that ERα is required for the E2-stimulated bone formation (32) and suggest that ASPP 049 activated Wnt/β-catenin signaling via the non-genomic estrogenic action.

Axin2 is a negative regulator of Wnt/β-catenin signaling by promoting the degradation of β-catenin in the proteasome (33). Activation of Wnt/β-catenin through TCF/LEF sites induces the transcription of Axin2 (33). In our study, Axin2 mRNA was rapidly (within 1 h) up-regulated by ASPP 049, followed by a suppression from 6 to 24 h. Then, the expression was again increased at 48 h. This pattern of Axin2 expression is consistent with the role of this protein in maintaining the cytosolic β-catenin at a steady state by a negative feedback mechanism, and that the Axin2 gene is the downstream target of β-catenin (33). Loss of Axin2 was associated with increased proliferation of osteoblast cells (34). The enhanced proliferation of MC3T3-E1 cells by ASPP 049 as early as 24 h in this study is likely related with the decrease in Axin2 expression. On the other hand, RUNX2 is a transcription factor that plays a major role in chondrocyte and osteoblast differentiation (35). However, it is still unclear how this protein regulates these processes. Activation of Wnt signaling up-regulates Runx2 gene expression and activates RUNX2 protein (36). Our finding that ASPP 049 markedly increases RUNX2 mRNA expression further confirms the action of this diarylheptanoid through Wnt/β-catenin signaling. That the expression of this gene is down-regulated at 6 h and then again up-regulated could be explained by mutual regulations between RUNX2 and Wnt/β-catenin signaling (35).

The mechanism underlying the effect of ASPP 049 on bone formation is not known at present. However, it has been shown in MC3T3-E1 cells that E2 and genistein induce the production of bone formation markers through estrogen receptors (37). E2-induced prevention of bone loss is mediated through the suppression of osteoclastogenesis by stimulating the production of insulin-like growth factor 1 (IGF-1), modulating the expression of osteoprotegerin and receptor activator of NF-κB ligand (RANKL) in osteoblastic cells (38). Indeed, Wnt signaling regulates the expression of receptor activator of NF-κB ligand and inhibits osteoclastogenesis (23). Therefore, it is likely that ASPP 049 exerts its action on osteoblastic cell proliferation and differentiation via similar mechanisms.

In conclusion, the diarylheptanoid, ASPP 049, from C. comosa, mediated its estrogenic activity through the ERα signaling pathway to activate Wnt/β-catenin signaling, which, in turn, induced osteoblastic cell proliferation and differentiation. Our findings shed light on the action of ASPP 049 on bone cells and provide a scientific rationale for using C. comosa as a dietary supplement to prevent bone loss in postmenopausal women.

Acknowledgments—We thank Dr. Chumpol Pholpramool for critical reading and comments on the manuscript.

REFERENCES
1. Gordon, M. D., and Nusse, R. (2006) Wnt signaling. Multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 281, 22429–22433
2. Moon, R. T., Kohn, A. D., De Ferrari, G. V., and Kaykas, A. (2004) WNT signaling. Multiple receptors, and multiple transcription factors. Nat. Rev. Genet. 5, 691–701
3. Chien, A. I., Conrad, W. H., and Moon, R. T. (2009) A Wnt survival guide. From flies to human disease. J. Invest. Dermatol. 129, 1614–1627
4. Varela, O., Arevalo, M. A., Garrido, J. I., Garcia-Segura, L. M., Wadnosell, F., and Mendez, P. (2010) Interaction of estrogen receptors with insulin-like growth factor-I and Wnt signaling in the nervous system. Steroids 75, 565–569
5. Armstrong, V. J., Muzylak, M., Sunters, A., Zaman, G., Saxon, L. K., Price, J. S., and Lanyon, L. E. (2007) Wnt/β-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor α. J. Biol. Chem. 282, 20715–20727
6. Westendorf, J. J., Kahler, R. A., and Schroeder, T. M. (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341, 19–39
Diarylheptanoid Activates Wnt/β-Catenin Signaling Pathway

7. Gong, Y., Skee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., Zacharin, M., Oexle, K., Marcelino, J., Suwairi, W., Heeger, S., Sabatagos, A., Gep, S., Adkins, W. N., Allgrove, J., Arslan-Kirchner, M., Batch, J. A., Brightdon, P., Black, G. C., Boles, R. G., Boon, L. M., Borromeo, C., Brunner, H. G., Carle, G. F., Dallapiccola, B., De Paepe, A., Floege, B., Halfhide, M. L., Hall, B., Hennekam, R. C., Hirose, T., Jans, A., Jüppner, H., Kim, C. A., Keppler-Noreuil, K., Kohlschuetter, A., LaCombe, D., Lambert, M., Lemyre, E., Letteboer, T., Peltonen, L., Ramesar, S. R., Romanenko, M., Somer, H., Steichen-Gersdorf, E., Steinmann, B., Sullivan, B., Superti-Furga, A., Swoboda, W., van den Boogaard, M. J., Van Hul, W., Vikkula, M., Votruba, M., Zabel, B., Garcia, T., Baron, R., Olsen, B. R., and Warman, M. L. (2011) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513–523.

8. Krishnan, V., Bryant, H. U., and Macdougall, O. A. (2006) Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116, 1202–1209.

9. Seeman, E., Szmucler, G. I., Formica, C., Tsalamandris, C., and Mistrock, R. (1992) Osteoporosis in anorexia nervosa. The influence of peak bone density, bone loss, oral contraceptive use, and exercise. J. Bone Miner. Res. 7, 1467–1474.

10. Harada, S., and Rodan, G. A. (2003) Control of osteoblast function and regulation of bone mass. Nature 423, 349–355.

11. Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., and Speizer, F. E. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332, 1589–1593.

12. Wood, C. E., Kaplan, J. R., Fontenot, M. B., Williams, J. K., and Cline, J. M. (2010) Endometrial profile of tamoxifen and low-dose estradiol combination therapy. Clin. Cancer Res. 16, 946–956.

13. Piaycharuatur, P., Ercharuporn, S., and Suksamrarn, A. (1995) Estrogenic activity of Curcuma comosa extract in rats. Asia Pacific Journal of Pharmacology 10, 121–126.

14. Weerachayaphorn, J., Chuncharunee, A., Mahagata, C., Lewchalerm-wongse, B., Suksamrarn, A., and Piaycharuatur, P. (2011) A protective effect of Curcuma roxb. on bone loss in estrogen-deficient mice. J. Ethnopharmacol. 137, 956–962.

15. Suksamrarn, A., Ponglikitmongkol, M., Wongkrajang, K., Chindaduang, A., Kittidanairak, S., Jankam, A., Yingyongnarongkul, B. E., Kittipanumat, G., Nekam, R. C., Hirose, T., Janss, A., Ju¨ppner, H., Kim, C. A., Keppler-Noreuil, G. C., Boles, R. G., Boon, L. M., Borrone, C., Brunner, H. G., Carle, G. F., Vikkula, M., Votruba, M., Zabel, B., Garcia, T., Baron, R., Olsen, B. R., and Warman, M. L. (2011) A protective effect of Curcuma roxb. on bone loss in estrogen-deficient mice. J. Bone Miner. Res. 26, 1202–1209.

16. Kim, Y. S., Lee, J. K., Kim, C. S., Lee, K. H., Matsui, T., Rosenzweig, A., Taylor, W. G., Rubin, J. S., Perrell, M. A., and Lee, M. E. (2001) Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 276, 17479–17483.

17. Wandesell, F., Varea, O., Arevalo, M. A., and Garcia-Segura, L. I. (2011) J. Neuroendocrinol. 24, 191–194.

18. Spencer, G. J., Utting, I. C., Etheridge, S. L., Arnett, T. R., and Genever, P. G. (2006) Wnt signalling in osteoblasts regulates expression of the receptor activator of NF-κB ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci. 119, 1283–1296.

19. Kouzmenko, A. P., Takekaya, K., Ito, S., Furutani, T., Sawatsubashi, S., Maki, A., Suzuki, E., Kawasaki, Y., Akiyama, T., Tabata, T., and Kato, S. (2004) Wnt/β-catenin and estrogen signaling converge in vivo. J. Biol. Chem. 279, 40255–40258.

20. Liedert, A., Wagner, L., Seefried, L., Ebert, R., Jakob, F., and Ignatius, A. (2010) Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. Biochem. Biophys. Res. Commun. 394, 755–759.

21. Matsuzawa, S. I., and Reed, J. C. (2001) Siah-1, SIB, and EIB collaborate in a novel pathway for β-catenin degradation linked to p53 responses. Mol. Cell 7, 915–926.

22. Liu, J., Stevens, J., Rote, C. A., Yost, H. J., Hu, Y., Neufeld, K. L., White, R. L., and Matsunami, N. (2001) Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatos polysiposis coli protein. Mol. Cell 7, 927–936.

23. Chairomgdua, A., Smith, D. L., Pochard, P., Hull, M., and Caplan, M. J. (2010) Exosome release of β-catenin. A novel mechanism that antagonizes Wnt signaling. J. Cell Biol. 190, 1079–1091.

24. Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Jr., Woodgett, J. R., and Mills, G. B. (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 97, 11960–11965.

25. Li, M., Wang, X., Meintzer, M. K., Laessig, T., Birnbaum, M. J., and Heidenreich, K. A. (2000) Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 97, 11960–11965.

26. Armstrong, J. L., Bonav ud, S. M., Too le, B. J., and Yeaman, S. J. (2001) Regulation of glycogen synthesis by amino acids in cultured human muscle cells. J. Biol. Chem. 276, 952–956.

27. McDougall, K. E., Perry, M. J., Gibson, R. L., Colley, S. M., Korach, K. S., and Tobias, J. H. (2003) Estrogen receptor-α dependency of estrogen’s stimulatory action on cancerous bone formation in male mice. Endocrinology 144, 1994–1999.

28. Jho, E. H., Zhang, T., Domon, C., Joo, C. K., Freund, J. N., and Costantini, F. (2002) Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell Biol. 22, 1172–1183.

29. Yu, H. M., Jerchow, B., Sheu, T. J., Liu, B., Costantini, F., Puzas, J. E., Birchmeier, W., and Hsu, W. (2005) The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development 132, 1995–2005.

30. Komori, T. (2010) Regulation of bone development and extracellular matrix protein gene expression by RUNX2. Cell Tissue Res. 339, 189–195.

31. Gaur, T., Lengner, C. J., Hovhannisyan, H., Bhat, R. A., Bodine, P. V., Kommm, B. S., Javed, A., van Wijnen, A. J., Stein, J. L., Stein, G. S., and Lian, J. B. (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280, 33132–33140.

32. Chen, X., Garner, S. C., Quares, L. D., and Anderson, J. I. (2003) Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J. Nutr. Biochem. 14, 342–349.

33. Rubin, J., Ackert-Bicknell, C., L., Zhu, L., Fan, X., Murphy, T. C., Nanes, M. S., Marcus, R., Holloway, L., Beamer, W. G., and Rosen, C. J. (2002) IGF-1 regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. J. Clin. Endocrinol. Metab. 87, 4273–4279.